Kawin Technology Share-holding Co., Ltd.
Quick facts
Phase 3 pipeline
- KW-136
KW-136 is an investigational therapeutic agent in phase 3 development by Kawin Technology.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Kawin Technology Share-holding Co., Ltd. portfolio CI brief
- Kawin Technology Share-holding Co., Ltd. pipeline updates RSS
Frequently asked questions about Kawin Technology Share-holding Co., Ltd.
What is Kawin Technology Share-holding Co., Ltd.'s pipeline?
Kawin Technology Share-holding Co., Ltd. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include KW-136.
Related
- Sector hub: All tracked pharma companies